Radiopharm Theranostics (RDPTF) Other Non-Current Liabilities (2024 - 2025)
Radiopharm Theranostics' (RDPTF) quarterly Other Non-Current Liabilities came in at $5440.8 in Q2 2025, down 2.82% year-over-year from $5598.7 in Q2 2024, and down 99.36% quarter-over-quarter from $849544.0 in Q4 2024.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Other Non-Current Liabilities for 2 consecutive years, with $5440.8 the latest figure, recorded in Q2 2025.
- On a quarterly basis, Other Non-Current Liabilities fell 2.82% year-over-year to $5440.8 in Q2 2025; TTM through Jun 2025 was $5440.8, a 2.82% decrease from a year earlier, with the FY2025 full-year figure at $849544.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was $5440.8 for Q2 2025 at Radiopharm Theranostics, down from $849544.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $849544.0 in Q4 2024 and troughed at $5440.8 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 5,440.76 |
| Dec 31, 2024 | 849,544.00 |
| Jun 30, 2024 | 5,598.70 |